These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26466937)

  • 1. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
    Inoue D; Muraoka R; Okazaki R; Nishizawa Y; Sugimoto T
    Calcif Tissue Int; 2016 Feb; 98(2):114-22. PubMed ID: 26466937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
    Mawatari T; Muraoka R; Iwamoto Y
    Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.
    Shigematsu T; Muraoka R; Sugimoto T; Nishizawa Y
    BMC Nephrol; 2017 Feb; 18(1):66. PubMed ID: 28201994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T; Inoue D; Maehara M; Oikawa I; Shigematsu T; Nishizawa Y
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.
    Okazaki R; Muraoka R; Maehara M; Inoue D
    J Bone Miner Metab; 2019 Jan; 37(1):185-197. PubMed ID: 29737412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
    J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
    Iwasaki T; Takei K; Nakamura S; Hosoda N; Yokota Y; Ishii M
    Pediatr Int; 2008 Jun; 50(3):269-75. PubMed ID: 18533934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of concurrent treatment with vitamin K
    Tanaka S; Miyazaki T; Uemura Y; Miyakawa N; Gorai I; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
    J Bone Miner Metab; 2017 Jul; 35(4):385-395. PubMed ID: 27484436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial.
    Mawatari T; Ikemura S; Matsui G; Iguchi T; Mitsuyasu H; Kawahara S; Maehara M; Muraoka R; Iwamoto Y; Nakashima Y
    Bone Rep; 2020 Jun; 12():100275. PubMed ID: 32462056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.